Navigation Links
LeMaitre Vascular Announces Changes to Its Executive Management Team
Date:4/10/2008

BURLINGTON, Mass., April 10 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) today announced the departure of Kevin D. Kelly, Senior Vice President, North American Sales, to pursue other business opportunities and the appointment of Robert V. Linden to Vice President, North American Sales.

Mr. Linden has approximately six years North American sales experience with LeMaitre Vascular. He joined LeMaitre Vascular in July 2002 as a Sales Representative and has served in positions of increasing responsibility within the North American organization. Since January 2008, he has served as Director of Sales for the Eastern United States and Canada, supervising three of the company's five North American sales regions. From 2005 through 2007, Mr. Linden served as Regional Sales Manager. Prior to LeMaitre Vascular, Mr. Linden served as a sales representative at several medical device companies, including Vasca, Inc., Atrium Medical Corporation, Active Medical, Inc., and DePuy Orthopedics, Inc. Mr. Linden holds a B.A. in Marketing from The Pennsylvania State University.

LeMaitre Vascular Chairman and Chief Executive Officer George W. LeMaitre stated, "We want to thank Kevin Kelly for his contributions and we wish him the best. We are thrilled to promote Rob Linden to the position of Vice President, North American Sales. I have watched Rob succeed at our company in positions of increasing responsibility over the past six years. We believe he will build on this experience to provide effective leadership for our North American sales organization."

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures, and markets medical devices for the treatment of peripheral vascular disease. The company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803.

Certain statements set forth above that are not clearly historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge, these forward-looking statements are neither promises nor guarantees. The forward-looking statements made in this release are made only as of the date hereof, and the company disclaims any intention or responsibility for updating predictions or expectations contained in this release.


'/>"/>
SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. LeMaitre Vascular to Start Italian Sales Force
2. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
3. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
4. LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
5. LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System
6. LeMaitre Vascular, Inc. Schedules Fourth Quarter Results and Conference Call
7. LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
8. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
9. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
10. Pot bellies linked to early signs of cardiovascular disease
11. Air pollution linked to cardiovascular risk indices in healthy young adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. ... line of probiotics, Petbiotics ™, as they fondly call them. As animal ... groups networking for their non-profit organizations. Animal rescues across the nation face huge ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in ... efficacy of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... 2014. Each year, reproductive endocrinologists are required to report in vitro fertilization ... of professionals dedicated to the practice of assisted reproductive technologies in the United ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
Breaking Medicine Technology: